Immune rejection is an important obstacle to the use of allogeneic 'off-the-shelf'cells for
transplantation into immunocompetent patients. Genetic modification has emerged as a …

This year marks the tenth anniversary of the world's first transplantation of tissue generated
from induced pluripotent stem cells (iPSCs). There is now a growing number of clinical trials …

Background: Recent studies have unveiled disulfidptosis as a phenomenon intimately
associated with cellular damage, heralding new avenues for exploring tumor cell dynamics …

Abstract Cluster of differentiation 47 (CD47) occupies the outer membrane of human cells,
where it binds to soluble and cell surface receptors on the same and other cells, sculpting …

Immune attack by natural killer (NK) cells is a major hurdle for allogeneic off-the-shelf cell
therapy, especially when HLA molecules are removed. Gravina et al. 1 utilized a membrane …

Type 1 diabetes (T1D) arises from autoimmune-mediated destruction of insulin-producing
pancreatic beta cells. Recent advancements in the technology of generating pancreatic beta …

Immunogenicity limits the persistence of off-the-shelf, allogeneic cell therapies and
transplants. While ablation of human leukocyte antigen (HLA) removes most T cell and …

Induced pluripotent stem cells (iPSCs) have revolutionized regenerative medicine and gene
therapy, providing a groundbreaking approach to create patient-specific cells that can be …

抄録 がん免疫療法の領域では, 患者由来の T 細胞を体外で遺伝子改変して患者に投与する方法
の有効性が示されている. しかし, この方法ではコストや時間がかかる, 品質が不安定などの問題も …